Does 3 Months Therapy With Vitamin D + Peg + Ribavirin Improve Sustained Virologic Response (SVR) in Genotype 2, 3 Chronic Hepatitis C Patients?

• Status: Unknown status
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy obtaining sustained virologic response (SVR) in 80% of naïve patients with genotype 2,3. Studies rarely address the issues of improving host factors. The current study examines

1. Does 3 months therapy with Vitamin D+ Peg + Ribavirin could improve viral response and shorten treatment duration (from 24 weeks to 12 weeks)

2. whether Vitamin D levels predicts negative treatment outcome.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ziv Hospital
• Treatments: Ergocalciferols; Ribavirin; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• 18 to 65 years of age

• chronic genotype 2,3 HCV infection

• treatment Naive negative sero for HBV, HDV and HIV viral infections

• absolute neutrophil count of >1500 per cubic millimeter

• a platelet count of >90,000 per cubic millimeter normal hemoglobin level

Exclusion Criteria:

• decompensated liver disease (cirrhosis with CP score >9)

• another cause of clinically significant liver disease hepato cellular carcinoma

• psychiatric Disorder

• chronic heart failure

• pregnant women

• uncontrolled diabetes with retinopathy Arrhythmia Active CAD

• positive sero for HBV, HDV and HIV viral infections or other autoimmune liver disease